420 related articles for article (PubMed ID: 37069229)
1. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
[TBL] [Abstract][Full Text] [Related]
2. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
3. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
Nishimura CD; Pulanco MC; Cui W; Lu L; Zang X
Trends Mol Med; 2021 Mar; 27(3):207-219. PubMed ID: 33199209
[TBL] [Abstract][Full Text] [Related]
5. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
6. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
7. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
[TBL] [Abstract][Full Text] [Related]
8. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
9. The B7:CD28 family and friends: Unraveling coinhibitory interactions.
Burke KP; Chaudhri A; Freeman GJ; Sharpe AH
Immunity; 2024 Feb; 57(2):223-244. PubMed ID: 38354702
[TBL] [Abstract][Full Text] [Related]
10. The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
Kula A; Koszewska D; Kot A; Dawidowicz M; Mielcarska S; Waniczek D; Świętochowska E
Cells; 2024 May; 13(10):. PubMed ID: 38786018
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Binds to B7-1 Only
Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
[TBL] [Abstract][Full Text] [Related]
12. The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
Sankin A; Narasimhulu D; John P; Gartrell B; Schoenberg M; Zang X
Urol Oncol; 2018 Oct; 36(10):459-468. PubMed ID: 28495553
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities.
Ren X; Li Y; Nishimura C; Zang X
Genes Dis; 2022 Sep; 9(5):1181-1193. PubMed ID: 35873032
[TBL] [Abstract][Full Text] [Related]
14. The B7 family revisited.
Greenwald RJ; Freeman GJ; Sharpe AH
Annu Rev Immunol; 2005; 23():515-48. PubMed ID: 15771580
[TBL] [Abstract][Full Text] [Related]
15. B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy.
Chen X; Li J; Chen Y; Que Z; Du J; Zhang J
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499340
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
[TBL] [Abstract][Full Text] [Related]
17. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
Zhang W; Acuna-Villaorduna A; Kuan K; Gupta S; Hu S; Ohaegbulam K; Albanese J; Kaumaya M; Levy R; Hwang RR; Zang X; Lin J; Liu Q; Maitra R; Goel S
Clin Colorectal Cancer; 2021 Jun; 20(2):161-169. PubMed ID: 33745842
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of B7-CD28 costimulation in urologic malignancies.
Thompson RH; Kwon ED; Allison JP
Immunotherapy; 2009 Jan; 1(1):129-39. PubMed ID: 20445772
[TBL] [Abstract][Full Text] [Related]
20. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.
Liu C; Zhang G; Xiang K; Kim Y; Lavoie RR; Lucien F; Wen T
Cancer Immunol Immunother; 2022 Jul; 71(7):1549-1567. PubMed ID: 34739560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
